Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007011041) GENETICALLY MODIFIED ANTIBODY COMPOSITION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/011041 International Application No.: PCT/JP2006/314531
Publication Date: 25.01.2007 International Filing Date: 21.07.2006
IPC:
C07K 16/46 (2006.01) ,A61K 39/395 (2006.01) ,C12N 5/10 (2006.01) ,C12N 15/09 (2006.01) ,C12P 21/08 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
08
Monoclonal antibodies
Applicants:
協和▲醗▼酵工業株式会社 KYOWA HAKKO KOGYO CO., LTD. [JP/JP]; 〒1008185 東京都千代田区大手町一丁目6番1号 Tokyo 6-1, Ohtemachi 1-chome Chiyoda-ku Tokyo1008185, JP (AllExceptUS)
設楽 研也 SHITARA, Kenya; null (UsOnly)
丹羽 倫平 NIWA, Rinpei; null (UsOnly)
夏目 暁人 NATSUME, Akito; null (UsOnly)
Inventors:
設楽 研也 SHITARA, Kenya; null
丹羽 倫平 NIWA, Rinpei; null
夏目 暁人 NATSUME, Akito; null
Priority Data:
2005-21297922.07.2005JP
2006-10821611.04.2006JP
Title (EN) GENETICALLY MODIFIED ANTIBODY COMPOSITION
(FR) COMPOSITION D'ANTICORPS GÉNÉTIQUEMENT MODIFIÉ
(JA) 遺伝子組換え抗体組成物
Abstract:
(EN) A human IgG1 antibody having the substitution of a polypeptide including a CH2 domain present in the Fc region by a polypeptide comprising an amino acid sequence corresponding to the amino acid sequence present at the same position as numbered according to the EU index as in Kabat et al. in a human IgG3 antibody; a genetically modified antibody composition having a higher complement-dependent cytotoxic activity than a human IgG3 antibody; an antibody molecule contained in the genetically modified antibody composition; DNA encoding the heavy-chain constant region of the antibody molecule; a transformant produced by introducing the DNA into a host cell; a method for production of a genetically modified antibody composition using the transformant; and a pharmaceutical comprising the genetically modified antibody composition as an active ingredient.
(FR) Anticorps IgG1 humain ayant un polypeptide comprenant un domaine CH2 présent dans la région Fc remplacé par un polypeptide comprenant une séquence d'acides aminés correspondant à la séquence d'acides aminés présente dans un anticorps IgG3 humain à la même position que celle que numérotée selon l'index EU de Kabat et al. ; composition d'anticorps génétiquement modifié ayant une activité cytotoxique dépendante du complément supérieure à celle d'un anticorps IgG3 humain ; molécule d'anticorps contenue dans la composition d'anticorps génétiquement modifié ; ADN codant pour la région constante de la chaîne lourde de la molécule d'anticorps ; transformant produit en introduisant l'ADN dans une cellule hôte ; procédé pour la production d'une composition d'anticorps génétiquement modifié utilisant le transformant ; et produit pharmaceutique comprenant la composition d'anticorps génétiquement modifié comme ingrédient actif.
(JA)  本発明は、 ヒトIgG1抗体において、Fc領域中のCH2ドメインを含むポリペプチドが、KabatらによるEUインデックスにおいてヒトIgG3抗体の同じ位置に相当するアミノ酸配列からなるポリペプチドに置換された、ヒトIgG1抗体およびヒトIgG3抗体よりも高い補体依存性細胞傷害活性を示す遺伝子組換え抗体組成物、該遺伝子組換え抗体組成物に含まれる抗体分子または該抗体分子の重鎖定常領域をコードするDNA、該DNAを宿主細胞に導入して得られる形質転換体、該形質転換体を用いた遺伝子組換え抗体組成物の生産方法、ならびに該遺伝子組換え抗体組成物を有効成分として含有する医薬に関する。
front page image
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)
Also published as:
KR1020080039907EP1921090CN101287765CA2616256JP4997108AU2006270718